We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The EMA’s Committee for Medicinal Products for Human Use recommended seven medicines at its Dec. 10-13 meeting for approval by the European Commission. Read More
The agency based its approval on a Phase 3 trial that showed the regimen led to patients living significantly longer than with Avastin and chemotherapy alone. Read More